Linda Mileshkin

Peter MacCallum Cancer Centre

Papers

1

Total Citations

47

H-Index

1

About

Linda Mileshkin is a leading Australian gynaecological oncologist and clinician-researcher whose work has fundamentally shaped the management of endometrial and ovarian cancers. Her primary research focuses on refining surgical staging, optimizing chemotherapy regimens, and improving quality of life for women with gynaecological malignancies. She is internationally recognized for her leadership in practice-changing clinical trials through the Australia New Zealand Gynaecological Oncology Group (ANZGOG). A landmark contribution is her work on the ENDO-3 trial, a phase III randomized study investigating sentinel node biopsy versus no retroperitoneal node dissection in apparent early-stage endometrial cancer, which has garnered 47 citations and directly addresses the critical balance between accurate staging and surgical morbidity. Beyond this, her research has explored novel therapeutic combinations and the integration of patient-reported outcomes into trial design. With a career spanning hundreds of publications and numerous collaborative international trials, Mileshkin’s impact is measured not only in citations but in the tangible reduction of treatment side effects and the personalization of care for women facing gynaecological cancers.

Research Focus

Key Achievements

1
H-Index
1
Papers
47
Total Citations
47
Avg Citations/Paper
🏆 Most Cited Paper
A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020
47 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Peter MacCallum Cancer Centre

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago